Distinguished in Peeling Skin Syndrome

Yasushi Suga

Urayasu, JP 
Distinguished in Peeling Skin Syndrome
Urayasu, JP 
OverviewLocationsClinical Research

Overview

Yasushi Suga practices in Urayasu, Japan. Suga and is rated as a Distinguished expert by MediFind in the treatment of Peeling Skin Syndrome. Their top areas of expertise are Epidermolytic Hyperkeratosis, Erythroderma, Exfoliative Dermatitis, and Peeling Skin Syndrome.

Their clinical research consists of co-authoring 93 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Peeling Skin Syndrome.

Locations

Urayasu, Japan
Other Locations
Tokyo, Japan
Chiba, Japan
Nagoya, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

93 Total Publications

Tinea Capitis Caused by Trichophyton tonsurans That Responded to Fosravuconazole.
Tinea Capitis Caused by Trichophyton tonsurans That Responded to Fosravuconazole.
Journal: Medical mycology journal
Published: June 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Suga's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile